Q-omics provides the consensus-scored C9orf78 profile across patient tissues and cancer cell-line models. C9orf78 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C9orf78 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, C9orf78 protein abundance shows 23,839 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where C9orf78 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf78 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf78 survival associations across molecular data types. C9orf78 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf78 RNA expression–survival associations across cancer types. High C9orf78 expression shows unfavorable associations in ACC, COAD and HNSC, but favorable associations in SCLC, KIRC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C9orf78 RNA expression.
This table summarizes C9orf78 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C9orf78. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf78 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, STAD and LUSC. The HNSC box plot shows higher C9orf78 RNA expression in tumor versus normal tissue (log2 FC = +1.054, t-test p < 0.001).
This table shows molecular features associated with C9orf78 in patient tissues and cancer cell lines. In patient samples, C9orf78 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf78 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
